NDMA SUPPORTS FDA's CURRENT "CASE-BY-CASE" OTC ANALGESIC POLICY
This article was originally published in The Tan Sheet
Executive Summary
NDMA SUPPORTS FDA's CURRENT "CASE-BY-CASE" OTC ANALGESIC POLICY in an Aug. 12 letter from Senior VP/Director-Science and Technology William Soller, PhD. Responding to an FDA backgrounder prepared for the upcoming Sept. 8-9 advisory subcommittee meeting on OTC analgesic labeling, Soller said the Nonprescription Drug Manufacturers Association "supports the current policy used by the agency for the review and approval of OTC analgesic drug products which encompasses a flexible, case-by-case, weight-of-the-evidence approach."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning